Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Daewoong Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Daewoong Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Daewoong Pharmaceutical Co., Ltd. - The report provides overview of Daewoong Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Daewoong Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Daewoong Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Daewoong Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Daewoong Pharmaceutical Co., Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Daewoong Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Daewoong Pharmaceutical Co., Ltd. Snapshot 7 Daewoong Pharmaceutical Co., Ltd. Overview 7 Key Information 7 Key Facts 7 Daewoong Pharmaceutical Co., Ltd. - Research and Development Overview 8 Key Therapeutic Areas 8 Daewoong Pharmaceutical Co., Ltd. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Daewoong Pharmaceutical Co., Ltd. - Pipeline Products Glance 14 Daewoong Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Daewoong Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Daewoong Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Daewoong Pharmaceutical Co., Ltd. - Drug Profiles 20 DWJ-1261 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 nepidermin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 onabotulinumtoxin A 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 (olmesartan medoxomil + rosuvastatin calcium) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 DWP-05195 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 DWC-20151 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 DWC-20152 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 DWP-09031 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 DWP-10292 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 DWP-14012 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 DWJ-1303 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 DWJ-1308 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 DWJ-1325 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 DWJ-1340 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 DWJ-1351 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 DWJ-1355 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 DWJ-1365 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 DWJ-1366 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 DWJ-206 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 DWJ-208 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 DWJ-209 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 DWP-06081 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Protein for Undisclosed Indication 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 DWJ-1367 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 DWJ-205 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 DWJ-210 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 DWP-457 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Daewoong Pharmaceutical Co., Ltd. - Pipeline Analysis 47 Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Target 47 Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 48 Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 49 Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 50 Daewoong Pharmaceutical Co., Ltd. - Recent Pipeline Updates 51 Daewoong Pharmaceutical Co., Ltd. - Dormant Projects 52 Daewoong Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 53 Discontinued Pipeline Product Profiles 53 lagociclovir 53 Daewoong Pharmaceutical Co., Ltd. - Company Statement 54 Daewoong Pharmaceutical Co., Ltd. - Locations And Subsidiaries 55 Head Office 55 Other Locations & Subsidiaries 55 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Daewoong Pharmaceutical Co., Ltd., Key Information 7 Daewoong Pharmaceutical Co., Ltd., Key Facts 7 Daewoong Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 9 Daewoong Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11 Daewoong Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12 Daewoong Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 13 Daewoong Pharmaceutical Co., Ltd. - Pre-Registration, 2016 14 Daewoong Pharmaceutical Co., Ltd. - Phase III, 2016 15 Daewoong Pharmaceutical Co., Ltd. - Phase II, 2016 16 Daewoong Pharmaceutical Co., Ltd. - Phase I, 2016 17 Daewoong Pharmaceutical Co., Ltd. - Preclinical, 2016 18 Daewoong Pharmaceutical Co., Ltd. - Discovery, 2016 19 Daewoong Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 47 Daewoong Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 48 Daewoong Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 49 Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 50 Daewoong Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016 51 Daewoong Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016 52 Daewoong Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016 53 Daewoong Pharmaceutical Co., Ltd., Other Locations 55 Daewoong Pharmaceutical Co., Ltd., Subsidiaries 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
